Project Number 5R37AG018440-08 Agency/Funding Organization NIA Funding Year 2008 View Full Project Details for ALPHA-SYNUCLEIN CLEARANCE STRATEGIES FOR THE TREATMENT OF LEWY BODY DISEASE Research Categorization Primary Disease / Condition Lewy Body Dementias CADRO Category A. Molecular Pathogenesis and Physiology of Alzheimer's Disease and Alzheimer's Disease-related Dementias (AD/ADRDs) 5. Other Proteinopathies a. Alpha-Synuclein Researcher and Organization Principal Investigator MASLIAH, ELIEZER Principal Investigator First Name ELIEZER Principal Investigator Last Name MASLIAH Awardee Organization UNIVERSITY OF CALIFORNIA SAN DIEGO Awardee State California Contact PI Country United States Project Detail FY Overall Cost $295,069 Funding Organization Agency/Funding Organization NIA Funding Organization Country United States Program Official BUCKHOLTZ, NEIL Related Resources Repository [AlzPED] Peptides of presenilin-1 bind the amyloid precursor protein ectodomain and offer a novel and specific therapeutic approach to reduce ß-amyloid in Alzheimer's disease [AlzPED] Novel therapeutic strategy for neurodegeneration by blocking Aβ seeding mediated aggregation in models of Alzheimer's disease. [AlzPED] Neural stem cells genetically-modified to express neprilysin reduce pathology in Alzheimer transgenic models. [AlzPED] A Neuroprotective Brain-penetrating Endopeptidase Fusion Protein Ameliorates Alzheimer Disease Pathology and Restores Neurogenesis [AlzPED] Peripheral delivery of a CNS targeted, metalo-protease reduces aβ toxicity in a mouse model of Alzheimer's disease. [AlzPED] Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation. [AlzPED] Amelioration of the cerebrovascular amyloidosis in a transgenic model of Alzheimer's disease with the neurotrophic compound cerebrolysin. Patent Compounds for reversing and inhibiting protein aggregation| and methods for making and using them Transgenic mouse model for neurodegenerative diseases
